October 12, 2023
Swimming upstream
Years ago, Diabetic Investor felt alone in the wilderness when we were the only publication that came out against Exubera. Everyone and we do mean everyone thought this was going to be a multi-billion-dollar drug. That was everyone but us. We accurately predicted that Exubera would be a colossal failure heck we even said so on CNBC.
We swam upstream again when all the analysts said no one would use Byetta the first FDA approved GLP-1 because it had to be injected twice a day. We noted that the needle was not the size of a nuclear . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
